A Pre-commercial Biopharma Focusing on Gastrointestinal Therapies
A pre-commercial biopharmaceutical company that focused on the development and commercialization of novel gastrointestinal (GI) therapies, had multiple drugs in the pipeline for 2018. However, they lacked the reliable data needed for efficient and agile new drug launches apart from facing the risk of violating any compliance or regulatory requirements. They had no commercial infrastructure and no data-driven insight into the target market. New drug launches required greater coordination across the entire organization, including market access, medical affairs, patient services, regulatory, marketing and sales. They needed a modern approach to data management to manage customer information and meet regulatory requirements.
Reltio Cloud was used to deploy healthcare provider (HCP) 360 with 250K+ aggregated profiles in less than 11 weeks to meet the timing of their product approval and launch. As a result, they built out their commercial sales readiness capabilities particularly for their greenfield sales representatives and derived actionable insights such as territory-mapping, relevant target audience, and improvised sales incentive program. In addition, they were able to bring in healthcare organizations (HCO) and payer data quickly due to flexible and scalable data architecture of Reltio’s Self-Learning Data Platform and do HCP and HCO affiliation management via Reltio Self-Learning Graph. Thus, they were able to establish Master Data Management (MDM) as the foundation for their HCP Customer Master and support sales and marketing team for timely launch of their new drug in the market. In the high-stakes race to market for a novel drug class, they were able to beat their competitors to avoid any commercial disadvantage and make its drug available to the needy patients.